# CheckMate-67T (NCT04810078)

> A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04810078
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Clear Cell Renal Cell Carcinoma
- Interventions: Nivolumab and rHuPH20; Nivolumab
- Enrollment: 681
- Primary outcome: Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale
- Primary outcome: Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original Scale

## Commentary we found

- X threads: 19
- Podcasts: 15
- YouTube: 13

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-67t-nct04810078

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04810078", "email": "<work email>"}; the inbox owner confirms by the emailed link.